8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions

8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) specializing in addictions must master the complex psychopharmacology, pharmacokinetic interactions, and evidence-based behavioral therapies required to stabilize patients presenting with co-occurring severe mental illness (SMI)—including Bipolar I/II Disorder, Schizophrenia spectrum disorders, and Borderline Personality Disorder—co-occurring with severe polysubstance use.

---

1. Bipolar I & II Disorder with Co-Occurring Substance Use Disorders

Epidemiology & Clinical Interdependence

Among all major psychiatric conditions, Bipolar I and Bipolar II Disorders exhibit the highest comorbidity with substance use disorders, with lifetime prevalence estimates exceeding 60% to 65%. The relationship is bidirectional, pernicious, and mutually destabilizing:

• Manic Disinhibition: Hypomanic and manic episodes produce grandiosity, hypersexuality, impulsivity, and impaired risk appraisal, driving patients directly into binge substance use—predominantly stimulants (cocaine, methamphetamine) and alcohol.
• Dysphoric Self-Medication: Depressive and mixed episodes characterized by intense psychic pain, irritability, and insomnia frequently prompt heavy alcohol or sedative consumption in a desperate attempt to induce sleep or blunt emotional agony.
• Substance-Induced Destabilization: Stimulant and alcohol use accelerates episode frequency, triggers rapid cycling (≥4 mood episodes per year), precipitates treatment-refractory mixed states, and drastically elevates suicide completion rates.
• The Clinical Axiom: Mood stabilization is the absolute prerequisite for achieving durable substance use remission. Attempting to achieve sustained abstinence while mania or hypomania remains unmedicated is clinically futile.

The Manic-Substance Destabilization Cascade:

[Bipolar Diathesis: Unstable Cortico-Limbic Mood Regulation]
                         │
                         ▼
         [Acute Manic / Mixed Mood Onset]
    (Grandiosity, Decreased Sleep Need, Impulsivity)
                         │
                         ▼
         [Severe Substance Binge Episode]
      (Cocaine, Methamphetamine, Binge Alcohol)
                         │
                         ▼
[Profound Dopaminergic / Serotonergic Neurotransmitter Depletion]
                         │
                         ▼
       [Post-Binge Catastrophic Crash into MDD]
   (Intense Hopelessness, Severe Suicidality, Exhaustion)
                         │
                         ▼
[Urgent Chemical Re-Dosing: Rapid Cycling & Treatment Resistance]

Evidence-Based Pharmacotherapy for Bipolar-SUD Comorbidity

Mood Stabilizers

• Lithium Carbonate: The gold standard mood stabilizer with unique, independently verified antisuicidal properties. It effectively treats acute mania and provides maintenance against depressive and manic recurrences.
  • Therapeutic Serum Trough Levels: 0.8 to 1.2 mEq/L for acute mania; 0.6 to 1.0 mEq/L for maintenance.
  • Essential Safety Monitoring: Baseline and periodic serum creatinine, Blood Urea Nitrogen (BUN), estimated GFR, Thyroid Stimulating Hormone (TSH), calcium, and baseline ECG.
  • Critical SUD Safety Warning: Lithium has a very narrow therapeutic index. In patients with active Alcohol Use Disorder or stimulant dependence, episodes of dehydration, excessive diaphoresis, vomiting, diarrhea, or NSAID use dramatically decrease renal lithium clearance, precipitating severe lithium toxicity (coarse tremors, hyperreflexia, ataxia, confusion, seizures, acute tubular necrosis, and coma).
• Divalproex Sodium / Valproate: Particularly efficacious in patients with mixed manic states, rapid cycling, and co-occurring substance use, often demonstrating superior clinical retention compared to lithium in polysubstance cohorts.
  • Therapeutic Serum Trough Levels: 50 to 125 mcg/mL.
  • Essential Safety Monitoring: Baseline and periodic Liver Function Tests (LFTs: AST, ALT, Total Bilirubin), Complete Blood Count with differential (platelet counts), and serum ammonia if the patient develops unexplained lethargy or cognitive slowing (valproate-induced hyperammonemic encephalopathy).
  • Black Box Warnings & Cautions: Hepatotoxicity, pancreatitis, dose-dependent thrombocytopenia, and severe teratogenicity (major congenital malformations including neural tube defects / spina bifida and neurodevelopmental deficits). Strictly contraindicated in women of childbearing potential unless effective, reliable contraception is documented and alternative agents have failed.

Second-Generation Antipsychotics (SGAs)

• Quetiapine (XR/IR): FDA-approved for bipolar mania, bipolar maintenance, and bipolar depression. Demonstrates efficacy in reducing anxiety, treating insomnia, and stabilizing mood in patients with co-occurring AUD. Clinical Cautions: Sedation, significant weight gain, hypertriglyceridemia, insulin resistance, and potential for diversion/misuse in closed institutional or correctional settings ("quell", "baby heroin").
• Aripiprazole: A partial dopamine D2/D3 agonist and 5-HT1A partial agonist with 5-HT2A antagonism. Favorable metabolic profile, non-sedating, excellent for acute mania and maintenance. Caution for akathisia and impulse-control disorders (gambling, compulsive spending).
• Lurasidone: FDA-approved for bipolar depression (monotherapy or adjunctive with lithium/valproate). Favorable weight and lipid profile. Administration Requirement: Must be administered with food containing at least 350 calories to achieve adequate bioavailability.

Strict Avoidance of Antidepressant Monotherapy

Prescribing antidepressant monotherapy (SSRIs, SNRIs, TCAs, or MAOIs) without an effective therapeutic mood stabilizer in patients with Bipolar I or Bipolar II disorder is strictly contraindicated. Antidepressants trigger manic switches, precipitate severe irritable mixed states, accelerate cycle frequency, and induce rapid cycling—substantially worsening substance use and suicide risk.

---

2. Schizophrenia Spectrum Disorders with Co-Occurring SUD

The Tobacco Use Disorder Epidemic in Schizophrenia

Tobacco smoking prevalence among individuals diagnosed with schizophrenia ranges from 70% to greater than 80%, representing a rate three- to fourfold higher than the general population. This disproportionate smoking rate is driven by profound neurobiological factors:

• Alpha-7 Nicotinic Acetylcholine Receptor (α7-nAChR) Pathology: Post-mortem and genetic studies reveal severe deficits in low- and high-affinity nicotinic receptor expression in the hippocampus, thalamus, and prefrontal cortex of patients with schizophrenia.
• Sensory Gating Deficits (P50 Auditory Gating): Normal brains filter out repetitive, irrelevant environmental auditory stimuli. Patients with schizophrenia exhibit impaired P50 gating, resulting in sensory overload and cognitive fragmentation. High-dose nicotine consumption transiently corrects this P50 deficit, providing temporary relief from cognitive disorganization.
• Counteracting Antipsychotic Adverse Effects: Nicotine stimulates prefrontal dopamine release, mitigating antipsychotic-induced parkinsonism, cognitive slowing, and emotional blunting.

Critical Pharmacokinetic Interaction: Tobacco Smoke and CYP1A2 Induction

A vital advanced practice pharmacology pearl involves the metabolic interaction between tobacco smoke and psychotropics metabolized by Cytochrome P450 1A2 (CYP1A2):

• Mechanism: The polycyclic aromatic hydrocarbons (tar) in burned tobacco smoke—NOT nicotine itself—are potent, robust inducers of hepatic CYP1A2.
• Clinical Consequence: Heavy smokers require significantly higher doses of CYP1A2 substrates, most notably Clozapine and Olanzapine.
• The Smoking Cessation Toxicity Trap: When a patient stabilized on clozapine or olanzapine stops smoking (e.g., during hospital admission or starting a tobacco cessation program), the enzymatic induction ceases over 1 to 2 weeks. Consequently, CYP1A2 clearance plummets, and serum concentrations of clozapine can spike by 50% to 100%, precipitating severe, life-threatening toxicity (profound sedation, seizures, orthostatic hypotension, paralytic ileus, cardiac arrest).
• APRN Action: When a patient on clozapine or olanzapine reduces or ceases tobacco use, the APRN must proactively reduce the dose by 30% to 50%, monitor serum drug concentrations, and follow clinical signs of toxicity closely.

Tobacco Smoke - CYP1A2 Pharmacokinetic Interaction:

[Active Heavy Smoking]
(Polycyclic Aromatic Hydrocarbons)
          │
          ▼
[Potent Induction of Hepatic CYP1A2]
          │
          ▼
[Accelerated Clearance of Clozapine & Olanzapine]
(High daily doses required to achieve therapeutic levels)

────────────────── Patient Stops Smoking ──────────────────

[CYP1A2 Enzyme Induction Resolves over 1-2 Weeks]
          │
          ▼
[Hepatic Clearance Drops by 50%]
          │
          ▼
[Serum Clozapine Concentrations Spike Precipitously!]
(Clinical Toxicity: Delirium, Grand Mal Seizures, Paralytic Ileus, Aspiration)
          │
          ▼
[MANDATORY APRN ACTION: Proactively reduce dose by 30-50% & monitor levels]

Tobacco Cessation Pharmacotherapy in Schizophrenia

Tobacco cessation must be prioritized without fear of psychiatric destabilization:

• Dual Nicotine Replacement Therapy (NRT): Combining a high-dose long-acting transdermal nicotine patch (21 mg/day) with short-acting NRT (nicotine gum, lozenge, or nasal spray) provides basal coverage while quenching acute breakthrough cravings.
• Varenicline: An α4β2 nicotinic acetylcholine receptor partial agonist. The landmark EAGLES trial established that varenicline is highly effective and does not increase neuropsychiatric adverse events, suicidal ideation, or psychotic exacerbations in stable psychiatric populations. It represents the most effective single oral agent for tobacco cessation in schizophrenia.

Cannabis, Stimulants & Second-Generation Long-Acting Injectables (LAIs)

• Cannabis & Psychosis: High-potency cannabis (delta-9-THC) and synthetic cannabinoids (K2/Spice) are potent triggers of acute psychotic exacerbations, accelerate conversion from prodromal states to formal schizophrenia, and increase psychiatric rehospitalizations by twofold.
• Second-Generation LAI Antipsychotics: The cornerstone of integrated management in co-occurring schizophrenia and SUD. Cognitive deficits, executive dysfunction, and episodic substance binges severely undermine oral pill adherence. LAIs decouple medication delivery from daily substance cravings:
  • Paliperidone Palmitate (Invega Sustenna / Trinza): Administered monthly or every 3 months. Maintains steady-state D2 receptor blockade without daily cognitive decision-making.
  • Aripiprazole Lauroxil (Aristada) / Aripiprazole Monohydrate (Abilify Maintena): Administered every 4 to 8 weeks. Low metabolic risk, partial agonist profile.
  • Clinical Impact: LAIs dramatically reduce psychotic relapses, decrease substance use frequency, prevent emergency department visits, and eliminate the risk of accidental overdose resulting from erratic oral dosing.
• Clozapine's Unique Anti-Addiction Efficacy: Clozapine is the gold-standard atypical antipsychotic for treatment-resistant schizophrenia. Uniquely, numerous clinical trials demonstrate that clozapine produces substantial, direct reductions in alcohol, cannabis, and cocaine cravings and consumption. Clozapine requires strict monitoring of the Absolute Neutrophil Count (ANC) via the national Clozapine REMS system (discontinue if ANC falls <1000/mcL due to risk of fatal agranulocytosis).

---

3. Borderline Personality Disorder (BPD) & Severe Polysubstance Use

The Clinical Challenge

Borderline Personality Disorder (BPD) co-occurs with substance use disorders in over 50% of clinical cases. BPD is characterized by pervasive patterns of affective dysregulation, intense fear of abandonment, chronic feelings of emptiness, extreme interpersonal reactivity, severe impulsivity, and recurrent non-suicidal self-injury (NSSI) or suicide gestures. Polysubstance misuse functions as an external chemical attempt to escape unbearable emotional agony and regulate overwhelming inner distress.

Dialectical Behavior Therapy (DBT) Adapted for SUD (DBT-SUD)

Developed by Marsha Linehan, DBT is the definitive evidence-based psychotherapeutic intervention for BPD. For co-occurring substance use, specific adaptations (DBT-SUD) are integrated into standard treatment:

Core Components of Linehan's DBT-SUD Framework:

1. Dialectical Abstinence:
   Synthesis of two polarized clinical stances:
   [Absolute Commitment to Abstinence] <── DIALECTICAL SYNTHESIS ──> [Radical Acceptance & Rapid Harm Reduction]
   • Stance A: "Never using again is the only goal; 100% commitment right now."
   • Stance B: "If a slip occurs, eliminate shame, analyze the lapse instantly, and resume recovery within hours."

2. Behavioral Chain Analysis (BCA):
   Meticulous micro-analysis of every lapse:
   [Vulnerability Factors] ──> [Prompting Event] ──> [Cognitive / Emotional Links] ──> [Substance Urge] ──> [Use Behavior] ──> [Consequences]

3. The Four Core Skill Modules:
   • Mindfulness: Wise Mind; observing and describing emotions non-judgmentally.
   • Distress Tolerance: TIPP skills (Temperature, Intense exercise, Paced breathing, Paired muscle relaxation); urge surfing.
   • Emotion Regulation: Identifying emotions, opposite action to change unhelpful emotional states.
   • Interpersonal Effectiveness: DEAR MAN; setting firm interpersonal boundaries, asserting needs without conflict.

• Dialectical Abstinence: Traditional addiction treatment insists on absolute abstinence, which can induce the disastrous "abstinence violation effect" (a slip leads to total collapse, overwhelming shame, and catastrophic relapse). Conversely, pure harm reduction may unintentionally endorse complacency. Dialectical abstinence synthesizes these polarities: the patient makes a 100% commitment to total abstinence prior to any use, but if a slip occurs, the clinician immediately activates radical acceptance, eliminates moral judgment, conducts an immediate behavioral chain analysis, and restores safety within hours.
• Attachment Strategies & Therapist Boundaries: Patients with BPD often alternate between idealization and devaluation ("splitting") of clinical staff. The APRN must establish rock-solid professional boundaries, maintain consistent treatment parameters, avoid rescue fantasies, and utilize interprofessional team consultation to prevent clinician burnout.

Pharmacotherapy Safeguards & Prescribing Precautions in BPD

1. Strict Avoidance of Habit-Forming Controlled Substances: The prescription of PRN benzodiazepines, barbiturates, carisoprodol, or sedative-hypnotics is strictly contraindicated. Patients with BPD exhibit high impulsivity during acute interpersonal crises; access to PRN sedatives leads to rapid dose escalation, severe behavioral disinhibition, accidental or deliberate overdose, and perpetuates reliance on chemical coping.
2. Targeted Symptom Pharmacotherapy: Psychopharmacology plays an adjunctive, secondary role to DBT in BPD. Medications are selected for specific symptom dimensions:
   • Affective Instability / Anger: Low-dose mood stabilizers (e.g., lamotrigine, topiramate) or second-generation antipsychotics (e.g., low-dose aripiprazole, quetiapine).
   • Impulsivity / Dysphoria: SSRIs may provide modest benefits for co-occurring depressive or anxiety symptoms, though evidence for core BPD traits is limited.
3. Structured Crisis Plans: Patients must have an explicit, written behavioral crisis plan that prioritizes non-pharmacological distress tolerance (e.g., ice-water facial immersion [mammalian dive reflex], intense physical exercise, reaching out to DBT phone coaching) rather than emergency room visits for sedative injections.

---

4. SMI, SUD Interactions, and Pharmacotherapy Safeguards